The medication has been approved for weight management in individuals having a body mass index (BMI) equal to or exceeding 30 or a body mass index of 27 or above who possess at least one condition related to weight, like type 2 diabetes or elevated blood pressure
Importantly, the largest reductions in BMI were observed in the southern United States, which also reported the highest rates of GLP-1 RA dispensing claims (Rader et al., 2024), a geographic concordance that is consistent with a causal contribution of these pharmacotherapies to the observed population-level BMI decline
Do not expect overnight fairness
Quick answer: L-carnitine is most plausible for people with a real carnitine deficit or a context where trials show bigger effects: older adults, people with overweight or obesity, some metabolic-health populations, dialysis patients under medical care, and athletes using it for recovery over weeks, not days
Most studies included multiple doses of ROSE-010 and a placebo group
3a, b), but also fully normalised both grip strength recovery and endpoint grip strength to values similar to those in mice fed a standard diet (Fig